ALK and non-small cell lung carcinoma: A total of 324 patients with advanced NSCLC and no known EGFR, ALK, ROS1, or RET alterations who received PD-(L)1i as monotherapy (N = 323) or in combination with a CTLA-4i (N = 1), independent of line of therapy, were included.